RANDSTAD NV 24.360 € (-0,04 %)
ENGIE 28.150 € (+0,64 %)
AXA 42.450 € (-0,40 %)
WOLTERS KLUWER 69.320 € (-2,83 %)
ASML HOLDING 1 245.000 € (+0,08 %)
ORANGE 17.740 € (+3,50 %)
BNP PARIBAS ACT.A 92.600 € (-1,78 %)
VEOLIA ENVIRON. 35.510 € (-0,11 %)
SAINT GOBAIN 78.680 € (-3,39 %)
SOITEC 100.000 € (+2,23 %)
TOTALENERGIES 74.410 € (+1,83 %)
MERCIALYS 12.860 € (+0,16 %)
CSG 21.215 € (-0,86 %)
ARCELORMITTAL SA 52.900 € (-1,01 %)
Coca-ColaEuropacif 83.100 € (-0,84 %)
INNATE PHARMA 1.300 € (-5,52 %)
SMCP 5.820 € (-2,35 %)
ADYEN 970.800 € (-1,43 %)
FUGRO 10.630 € (-1,67 %)
VERALLIA 19.150 € (-1,49 %)
UNILEVER 49.310 € (-0,88 %)
CORBION 19.160 € (-0,57 %)
FIPP 0.138 € (+4,55 %)
STELLANTIS NV 7.342 € (-1,24 %)
MAISONS DU MONDE 0.660 € (-12,00 %)
ING GROEP N.V. 24.495 € (-0,71 %)
BAM GROEP KON 9.535 € (-1,60 %)
NETMEDIA GROUP 0.664 € (+24,81 %)
SHELL PLC 37.605 € (+2,41 %)
SBM OFFSHORE 34.680 € (+2,18 %)
AMG 35.960 € (+1,18 %)
MAGNUM 12.074 € (-2,20 %)
STMICROELECTRONICS 37.275 € (+0,17 %)
SCHNEIDER ELECTRIC 273.600 € (-1,81 %)
MICHELIN 32.240 € (-0,56 %)
EURONEXT 146.700 € (+0,62 %)
PUBLICIS GROUPE SA 78.740 € (-1,87 %)
NN GROUP 73.380 € (-0,24 %)
ASR NEDERLAND 63.680 € (-1,12 %)
DSM FIRMENICH AG 65.340 € (-0,64 %)
AIR LIQUIDE 186.380 € (+0,18 %)
LVMH 490.550 € (-1,77 %)
AHOLD DEL 41.300 € (+0,93 %)
PROSUS 43.995 € (-0,76 %)
ESSILORLUXOTTICA 206.500 € (-4,27 %)
ABN AMRO BANK N.V. 30.100 € (-1,38 %)
AIRBUS 176.380 € (-1,73 %)
VOPAK 42.560 € (+0,57 %)
VALEO 11.255 € (-3,10 %)
MYHOTELMATCH 0.154 € (-5,54 %)
DRONE VOLT 0.570 € (-3,23 %)
GTT 195.100 € (+0,31 %)
KAUFMAN ET BROAD 29.250 € (-1,02 %)
HERMES INTL 1 696.000 € (-2,58 %)
DANONE 67.960 € (-0,26 %)
SIDETRADE 163.000 € (+5,84 %)
CTP 16.320 € (-2,04 %)
WE.CONNECT 25.700 € (-1,91 %)
BASIC-FIT 31.640 € (-2,94 %)
ADP 112.100 € (-2,10 %) |
20/04/2026 13:00
Covation Biomaterials' First Commercial Plant for bioTHF and bioPTMEG Reaches Mechanical Completion; Xatryx®,Brand Unveiled for New Non-Food bioPTMEGEQS-News: Covation Biomaterials / Key word(s): ESG/Product Launch SHANGHAI, April 20, 2026 /PRNewswire/ -- Covation Biomaterials LLC ("CovationBio®"), a biomaterials company with advanced technology in the bio-based materials industry, announced today that its first commercial plant for the C4 product platform, including bioTHF and bio-based polytetramethylene ether glycol ("PTMEG"), achieved mechanical completion in April 2026. In addition, CovationBio now officially launches the Xatryx® brand for the portfolio of new, non-food, bioPTMEG products to be produced at the plant. ![]() This milestone marks a significant step forward in defossilization of material production, reinforcing the company's commitment to delivering high-performance, renewable-based solutions to the global market. The C4 facility is located in Qidong, Jiangsu Province, China. It utilizes an innovative, new-to-the-world process technology developed by CovationBio. With a total investment of RMB 10 billion, the plant is planned in three phases, targeting a future total capacity of 500,000 tons per year of bio-based materials. The first phase, which is now mechanically complete, has a 50,000-ton-per-year commercial production capacity for both bioTHF and bioPTMEG. Commercial production is expected to begin in the second half of 2026. Feifeng You, President of CovationBio, commented: A Sustainable Alternative to Fossil-Based PTMEG and not Competing with Food Sources As a second-generation bio-based material, Xatryx® bioPTMEG serves as a drop-in replacement to fossil-based PTMEG, helping customers reduce their reliance on non-renewable materials while maintaining the high-performance of our downstream material applications such as spandex, polyurethanes, and thermoplastic elastomers. Key sustainability benefits of Xatryx® bioPTMEG include:
Presence at CHINAPLAS 2026 Aligned with this year's CHINAPLAS theme, "Transformation - Collaboration - Sustainability," members of the CovationBio® team are ready to share more about how Xatryx® products can integrate into downstream materials and advance sustainability strategies with value chain partners. Visitors are invited to meet the team and learn more in Hall 1.2, Booth F77. For those interested in learning more, please contact: bioPTMEG@covationbio.com Disclaimer: The statements above regarding the product's life cycle analysis (LCA) and product performance are based on studies and tests conducted by Covation Biomaterials LLC. About CovationBio® Founded in 2022 and headquartered in Newark, Delaware, Covation Biomaterials LLC is a biomaterials company with advanced technology in the bio-based materials industry, offering a product portfolio of high-performance, sustainable solutions. The CovationBio® company builds on its rich DuPont legacy of groundbreaking scientific innovation and continues to deliver novel solutions at scale across multiple industries, including apparel, carpeting, and footwear. Through product lines such as Sorona® polymer and other bio-based materials, CovationBio's mission is to deliver building blocks that enable customers to provide bio-based products accessible to everyone. Covation, Covation Biomaterials, Xatryx® and Sorona® are trademarks of Covation Biomaterials LLC or its affiliates. For more information, please visit CovationBio.com and follow on WeChat, LinkedIn, Instagram, and Facebook. Photo - https://mma.prnewswire.com/media/2960334/Weixin_Image_20260420172652.jpg ![]() 20.04.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. 2311272 20.04.2026 CET/CEST Source : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière

